667 related articles for article (PubMed ID: 21720655)
21. Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial.
Spergel JM; Boguniewicz M; Paller AS; Hebert AA; Gallagher PR; McCormick C; Parneix-Spake A; Hultsch T
Br J Dermatol; 2007 Aug; 157(2):378-81. PubMed ID: 17573885
[TBL] [Abstract][Full Text] [Related]
22. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis.
Meurer M; Fartasch M; Albrecht G; Vogt T; Worm M; Ruzicka T; Altmeyer PJ; Schneider D; Weidinger G; Braeutigam M;
Dermatology; 2004; 208(4):365-72. PubMed ID: 15178928
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis.
Sigurgeirsson B; Ho V; Ferrándiz C; Andriano K; Grinienko A; Jimenez P;
J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1290-301. PubMed ID: 18624866
[TBL] [Abstract][Full Text] [Related]
24. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis.
Langley RG; Eichenfield LF; Lucky AW; Boguniewicz M; Barbier N; Cherill R
Pediatr Dermatol; 2008; 25(3):301-7. PubMed ID: 18577032
[TBL] [Abstract][Full Text] [Related]
25. Pimecrolimus 1% cream for the treatment of atopic dermatitis.
Wolff K
Skin Therapy Lett; 2005 Oct; 10(8):1-6. PubMed ID: 16292456
[TBL] [Abstract][Full Text] [Related]
26. An open-label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid-induced rosacea-like eruption.
Chu CY
J Eur Acad Dermatol Venereol; 2007 Apr; 21(4):484-90. PubMed ID: 17373975
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
[TBL] [Abstract][Full Text] [Related]
28. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis.
Kempers S; Boguniewicz M; Carter E; Jarratt M; Pariser D; Stewart D; Stiller M; Tschen E; Chon K; Wisseh S; Abrams B
J Am Acad Dermatol; 2004 Oct; 51(4):515-25. PubMed ID: 15389185
[TBL] [Abstract][Full Text] [Related]
29. Pimecrolimus and narrowband UVB as monotherapy or combination therapy in children and adolescents with atopic dermatitis.
Tzung TY; Lin CB; Chen YH; Yang CY
Acta Derm Venereol; 2006; 86(1):34-8. PubMed ID: 16585987
[TBL] [Abstract][Full Text] [Related]
30. Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild-to-moderate atopic dermatitis.
Aschoff R; Schwanebeck U; Bräutigam M; Meurer M
Exp Dermatol; 2009 Jan; 18(1):24-9. PubMed ID: 18637133
[TBL] [Abstract][Full Text] [Related]
31. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study.
Gribetz C; Ling M; Lebwohl M; Pariser D; Draelos Z; Gottlieb AB; Zaias N; Chen DM; Parneix-Spake A; Hultsch T; Menter A
J Am Acad Dermatol; 2004 Nov; 51(5):731-8. PubMed ID: 15523351
[TBL] [Abstract][Full Text] [Related]
32. Topical pimecrolimus 1% cream for resistant seborrheic dermatitis of the face: an open-label study.
Ozden MG; Tekin NS; Ilter N; Ankarali H
Am J Clin Dermatol; 2010; 11(1):51-4. PubMed ID: 20000875
[TBL] [Abstract][Full Text] [Related]
33. Pimecrolimus 1% cream for the treatment of steroid-induced rosacea: an 8-week split-face clinical trial.
Lee DH; Li K; Suh DH
Br J Dermatol; 2008 May; 158(5):1069-76. PubMed ID: 18363758
[TBL] [Abstract][Full Text] [Related]
34. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life.
McKenna SP; Whalley D; de Prost Y; Staab D; Huels J; Paul CF; van Assche D
J Eur Acad Dermatol Venereol; 2006 Mar; 20(3):248-54. PubMed ID: 16503881
[TBL] [Abstract][Full Text] [Related]
35. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis.
Fleischer AB; Abramovits W; Breneman D; Jaracz E;
J Dermatolog Treat; 2007; 18(3):151-7. PubMed ID: 17538803
[TBL] [Abstract][Full Text] [Related]
36. Pimecrolimus cream 1%: a new development in nonsteroid topical treatment of inflammatory skin diseases.
Hebert AA; Warken KA; Cherill R
Semin Cutan Med Surg; 2001 Dec; 20(4):260-7. PubMed ID: 11770913
[TBL] [Abstract][Full Text] [Related]
37. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial.
Rigopoulos D; Ioannides D; Kalogeromitros D; Gregoriou S; Katsambas A
Br J Dermatol; 2004 Nov; 151(5):1071-5. PubMed ID: 15541087
[TBL] [Abstract][Full Text] [Related]
38. Spotlight on topical pimecrolimus in atopic dermatitis.
Wellington K; Jarvis B
Am J Clin Dermatol; 2002; 3(6):435-8. PubMed ID: 12113651
[TBL] [Abstract][Full Text] [Related]
39. [Topical immunomodulators, such as tacrolimus and pimecrolimus, in the treatment of atopic dermatitis].
de Bruin-Weller MS; Bruijnzeel-Koomen CA
Ned Tijdschr Geneeskd; 2005 May; 149(20):1096-100. PubMed ID: 15932135
[TBL] [Abstract][Full Text] [Related]
40. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice.
Lübbe J; Friedlander SF; Cribier B; Morren MA; García-Díez A; Gelmetti C; Hofmann H; Houwing RH; Kownacki S; Langley RG; Virtanen M; Wolff K; Wisseh S; McGeown C; Abrams B; Schneider D;
Am J Clin Dermatol; 2006; 7(2):121-31. PubMed ID: 16605292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]